[
  {
    "ts": "2025-09-04T20:14:19+00:00",
    "headline": "Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'",
    "summary": "Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.",
    "url": "https://www.investors.com/news/technology/sanofi-stock-eczema-treatment-dupixent/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "244cab8d-e6a4-3862-bbd9-a619a6da3178",
      "content": {
        "id": "244cab8d-e6a4-3862-bbd9-a619a6da3178",
        "contentType": "STORY",
        "title": "Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'",
        "description": "",
        "summary": "Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.",
        "pubDate": "2025-09-04T20:14:19Z",
        "displayTime": "2025-09-04T20:14:19Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/244cab8d-e6a4-3862-bbd9-a619a6da3178/sanofi-tumbles-as-new-eczema.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/39552a8c730cc984b85b9f305609e672",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m5t8ruN3efQawYlxTXHjwQ--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/39552a8c730cc984b85b9f305609e672.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n5WZ_EOteqdcdGr66t5M5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/39552a8c730cc984b85b9f305609e672.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/sanofi-stock-eczema-treatment-dupixent/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T20:05:00+00:00",
    "headline": "Regeneron Announces Updated Presentation Time for Upcoming Investor Conference",
    "summary": "TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025. The presentation will be webcast live and may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcast will be archived on the Company's web",
    "url": "https://finance.yahoo.com/news/regeneron-announces-updated-presentation-time-200500606.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0dfc845b-b7f9-3441-9bf6-a0c15576f13a",
      "content": {
        "id": "0dfc845b-b7f9-3441-9bf6-a0c15576f13a",
        "contentType": "STORY",
        "title": "Regeneron Announces Updated Presentation Time for Upcoming Investor Conference",
        "description": "",
        "summary": "TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025. The presentation will be webcast live and may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcast will be archived on the Company's web",
        "pubDate": "2025-09-04T20:05:00Z",
        "displayTime": "2025-09-04T20:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-announces-updated-presentation-time-200500606.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-announces-updated-presentation-time-200500606.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T17:32:35+00:00",
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
    "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-bull-173235172.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d0bcb935-e635-3446-a2a3-9db3589133d1",
      "content": {
        "id": "d0bcb935-e635-3446-a2a3-9db3589133d1",
        "contentType": "STORY",
        "title": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
        "pubDate": "2025-09-04T17:32:35Z",
        "displayTime": "2025-09-04T17:32:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/05091c2b4af540bdca13bdc30e634918",
          "originalWidth": 1000,
          "originalHeight": 734,
          "caption": "10 Pharmacist Shortage Countries in Need of Pharmacists in 2017",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5Cgq4qWQpqkPoq.QRSiG3g--~B/aD03MzQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/05091c2b4af540bdca13bdc30e634918.cf.webp",
              "width": 1000,
              "height": 734,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j4x0D9A.Sa_MLOotI128Ng--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/05091c2b4af540bdca13bdc30e634918.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-bull-173235172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-bull-173235172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T14:48:00+00:00",
    "headline": "SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study",
    "summary": "Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.",
    "url": "https://finance.yahoo.com/news/sny-down-despite-eczema-candidate-144800148.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9acb7d02-1f33-3e00-9701-2aaca168ccc5",
      "content": {
        "id": "9acb7d02-1f33-3e00-9701-2aaca168ccc5",
        "contentType": "STORY",
        "title": "SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study",
        "description": "",
        "summary": "Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.",
        "pubDate": "2025-09-04T14:48:00Z",
        "displayTime": "2025-09-04T14:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o4IYsXmA1G0eGuhNw0c16g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/43AXa9s.CTUHOV5OT2wzjA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sny-down-despite-eczema-candidate-144800148.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sny-down-despite-eczema-candidate-144800148.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAN.PA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T03:32:26+00:00",
    "headline": "Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best",
    "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers.",
    "url": "https://finance.yahoo.com/news/immuno-oncology-q2-earnings-regeneron-033226800.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "afa4b39e-8e0d-3566-a903-1b46e542c1f7",
      "content": {
        "id": "afa4b39e-8e0d-3566-a903-1b46e542c1f7",
        "contentType": "STORY",
        "title": "Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best",
        "description": "",
        "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers.",
        "pubDate": "2025-09-04T03:32:26Z",
        "displayTime": "2025-09-04T03:32:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/immuno-oncology-q2-earnings-regeneron-033226800.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/immuno-oncology-q2-earnings-regeneron-033226800.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]